文献速递前列腺癌

活检初治男性中系统活检与mpMRI及CUDI靶向活检的前瞻性对比

Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy.
PubMed 文献 · BJU Int · 2020-05-13

这项前瞻性单中心配对诊断研究纳入150例活检初治男性,比较mpMRI靶向活检、CUDI靶向活检与12针系统活检对临床显著前列腺癌(csPCa)的检出。中期分析显示系统活检对GG≥2 PCa检出率显著更高(39% vs 29%和28%),研究因两种靶向策略劣于系统活检而提前终止。

要点

  • 系统活检对GG≥2 PCa检出率显著高于mpMRI和CUDI靶向活检。
  • mpMRI靶向活检假阳性率低于CUDI靶向活检(18% vs 53%)。
  • 两种靶向策略对GG≥2伴筛状/导管内癌及GG≥3 PCa检出无显著差异。

核心结论

  • 在活检初治男性中,mpMRI和CUDI靶向活检策略对GG≥2 PCa的检出劣于系统活检,研究因中期分析结果而提前终止。
  • 两种靶向策略检出率相当,但mpMRI靶向活检假阳性发现更少。
  • 两种靶向策略减少了无临床意义GG=1 PCa的检出,但对GG≥2伴CR/IDC及GG≥3 PCa的检出与系统活检无显著差异。

研究设计与样本

  • 所有男性先行mpMRI和CUDI检查,随后由对影像结果设盲的操作者进行12针系统活检。
  • 影像可疑病灶者再由第二操作者行MRI-TRUS融合靶向活检和/或认知融合CUDI靶向活检。
  • 对GG≥2 PCa采用非劣效性分析,非劣效界值为1个百分点;检出率差异用McNemar检验及调整Wald置信区间。

主要发现

  • 系统活检GG≥2 PCa检出率为39%(56/142),显著高于mpMRI靶向活检的29%(41/142)和CUDI靶向活检的28%(40/142)(P < 0.05)。
  • 系统活检GG=1 PCa检出率为14%(20/142),显著高于mpMRI靶向活检的1%(2/142)和CUDI靶向活检的3%(4/142)(P < 0.05)。
  • GG≥2伴CR/IDC和GG≥3 PCa的检出率在各策略间无显著差异。
  • mpMRI靶向活检假阳性率为18%,CUDI靶向活检为53%。

关键数值与推荐

  • 非劣效性界值为1个百分点,用于比较mpMRI和CUDI靶向活检策略与系统活检对GG≥2 PCa的检出。
  • GG≥2 PCa检出率:系统活检39%(56/142),mpMRI靶向活检29%(41/142),CUDI靶向活检28%(40/142),P < 0.05。
  • GG=1 PCa检出率:系统活检14%(20/142),mpMRI靶向活检1%(2/142),CUDI靶向活检3%(4/142),P < 0.05。
  • 假阳性率:mpMRI靶向活检18%,CUDI靶向活检53%。

临床怎么用

  • 在活检初治男性中,不应以mpMRI或CUDI靶向活检完全替代系统活检,因两者对GG≥2 PCa检出劣于系统活检。
  • 若采用靶向活检,mpMRI靶向策略假阳性发现少于CUDI靶向策略。
  • 靶向策略可减少无临床意义GG=1 PCa的检出,但需结合系统活检以确保GG≥2 PCa的检出。

局限性

  • 研究为单中心设计,样本量150例,中期分析后提前终止。
  • 研究未报告长期随访数据或成本效益分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare and evaluate a multiparametric magnetic resonance imaging (mpMRI)-targeted biopsy (TBx) strategy, contrast-ultrasound-dispersion imaging (CUDI)-TBx strategy and systematic biopsy (SBx) strategy for the detection of clinically significant prostate cancer (csPCa) in biopsy-naïve men. PATIENTS AND METHODS: A prospective, single-centre paired diagnostic study included 150 biopsy-naïve men, from November 2015 to November 2018. All men underwent pre-biopsy mpMRI and CUDI followed by a 12-core SBx taken by an operator blinded from the imaging results. Men with suspicious lesions on mpMRI and/or CUDI also underwent MRI-TRUS fusion-TBx and/or cognitive CUDI-TBx after SBx by a second operator. A non-inferiority analysis of the mpMRI- and CUDI-TBx strategies in comparison with SBx for International Society of Urological Pathology Grade Group [GG] ≥2 PCa in any core with a non-inferiority margin of 1 percentage point was performed. Additional analyses for GG ≥2 PCa with cribriform growth pattern and/or intraductal carcinoma (CR/IDC), and GG ≥3 PCa were performed. Differences in detection rates were tested using McNemar's test with adjusted Wald confidence intervals. RESULTS: After enrolment of 150 men, an interim analysis was performed. Both the mpMRI- and CUDI-TBx strategies were inferior to SBx for GG ≥2 PCa detection and the study was stopped. SBx found significantly more GG ≥2 PCa: 39% (56/142), as compared with 29% (41/142) and 28% (40/142) for mpMRI-TBx and CUDI-TBx, respectively (P < 0.05). SBx found significantly more GG = 1 PCa: 14% (20/142) compared to 1% (two of 142) and 3% (four of 142) with mpMRI-TBx and CUDI-TBx, respectively (P < 0.05). Detection of GG ≥2 PCa with CR/IDC and GG ≥3 PCa did not differ significantly between the strategies. The mpMRI- and CUDI-TBx strategies were comparable in detection but the mpMRI-TBx strategy had less false-positive findings (18% vs 53%). CONCLUSIONS: In our study in biopsy-naïve men, the mpMRI- and CUDI-TBx strategies had comparable PCa detection rates, but the mpMRI-TBX strategy had the least false-positive findings. Both strategies were inferior to SBx for the detection of GG ≥2 PCa, despite reduced detection of insignificant GG = 1 PCa. Both strategies did not significantly differ from SBx for the detection of GG ≥2 PCa with CR/IDC and GG ≥3 PCa.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Mannaerts CK, Engelbrecht MRW, Postema AW, et al. Detection of clinically significant prostate cancer in biopsy-naïve men: direct comparison of systematic biopsy, multiparametric MRI- and contrast-ultrasound-dispersion imaging-targeted biopsy. BJU Int. 2020. PMID: 32315112. doi:10.1111/bju.15093

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。